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Nanobodies effectively modulate 
the enzymatic activity of CD38 and 
allow specific imaging of CD38+ 
tumors in mouse models in vivo
William Fumey1,2, Julia Koenigsdorf1,2, Valentin Kunick1,2, Stephan Menzel1, Kerstin 
Schütze1,2, Mandy Unger1, Levin Schriewer1,2, Friedrich Haag1, Gerhard Adam2, Anna Oberle3, 
Mascha Binder3, Ralf Fliegert4, Andreas Guse4, Yong Juan Zhao  5, Hon Cheung Lee5, Fabio 
Malavasi6, Fernando Goldbaum7, Rob van Hegelsom8, Catelijne Stortelers8, Peter Bannas2 & 
Friedrich Koch-Nolte1
The cell surface ecto-enzyme CD38 is a promising target antigen for the treatment of hematological 
malignancies, as illustrated by the recent approval of daratumumab for the treatment of multiple 
myeloma. Our aim was to evaluate the potential of CD38-specific nanobodies as novel diagnostics for 
hematological malignancies. We successfully identified 22 CD38-specific nanobody families using phage 
display technology from immunized llamas. Crossblockade analyses and in-tandem epitope binning 
revealed that the nanobodies recognize three different non-overlapping epitopes, with four nanobody 
families binding complementary to daratumumab. Three nanobody families inhibit the enzymatic 
activity of CD38 in vitro, while two others were found to act as enhancers. In vivo, fluorochrome-
conjugated CD38 nanobodies efficiently reach CD38 expressing tumors in a rodent model within 
2 hours after intravenous injection, thereby allowing for convenient same day in vivo tumor imaging. 
These nanobodies represent highly specific tools for modulating the enzymatic activity of CD38 and for 
diagnostic monitoring CD38-expressing tumors.
CD38 is a 43 kDa type II transmembrane ecto-enzyme that is highly expressed in hematological malignancies 
including multiple myeloma1,2. CD38 consists of a short intracellular N-terminal domain, a transmembrane helix 
and a long C-terminal extracellular catalytic domain3. CD38 is a multifunctional enzyme that catalyzes the syn-
thesis of cyclic ADP-ribose and ADP-ribose from extracellular NAD+4,5. The presence of CD38 is routinely used 
as a marker for chronic lymphocytic leukemia (CLL) where high levels of CD38 correlates with a poor progno-
sis6. Binding of CD38 to its ligand CD31 enhances the proliferation and mirgration of CLL cells6,7. It has been 
proposed that the enzymatic activity of CD38 contributes to a microenvironment favorable for tumor survival in 
the bone marrow niche8. CD38 represents a promising target for monoclonal antibody (mAb)-based immuno-
therapy of multiple myeloma9–12. Daratumumab, a human IgG1 antibody generated by immunization of a human 
IgH-transgenic mouse, has shown promising results13,14. However, the use of mAbs has disadvantages that include 
the limited tissue penetration due to their large size of approximately 150 kD15,16
Nanobodies are the smallest antigen-binding domains derived from naturally occurring heavy chain anti-
bodies from camelids. These single domain antibodies have several advantages over conventional antibodies, 
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including the capacity to bind and block functional epitopes such as the active site cleft of enzymes, better tissue 
penetration in vivo, and the facile construction of bi- or multi-specific biologicals by genetic fusion15,17,18.
Binding of Daratumumab to CD38 prevents subsequent binding of many commercially available antibodies, 
which makes them unsuitable for plasma and myeloma cell identification in patients treated with daratumumab19. 
Thus, nanobodies that bind independently of daratumumab might be useful as companion diagnostic for identi-
fying CD38 expressing cells in patients treated with daratumumab. Moreover, the enzymatic activity of CD38 may 
contribute to immune suppression observed in myeloma patients and to a microenvironment that is favorable 
for tumor survival in the bone marrow niche8. Thus, nanobodies that modulate the enzymatic activity of CD38 
could have a therapeutic application for counteracting the immunosuppressive and tumor promoting activities 
of CD38.
Our goal was to evaluate the potential of CD38-specific nanobodies as novel diagnostics for hematologi-
cal malignancies. Using phage display technology we successfully generated human CD38-specific nanobodies 
from immunized llamas. We characterized these nanobodies in terms of CD38-binding on cells, modulation 
of enzymatic activity, affinity, epitope specificity, complementary binding to daratumumab and targeting of 
CD38-expressing tumors in a mouse model. The results suggest that some of these nanobodies hold promise for 
detecting and monitoring CD38-expressing tumors.
Results
Panning of VHH-phage display libraries from immunized llamas on CD38-transfected cells 
yields 22 distinct families of CD38-specific nanobodies. Two llamas were immunized with recombi-
nant nonglycosylated CD38 ecto-domain (aa 46–300) and two llamas were immunized with a cDNA expression 
vector encoding full length CD38 (Figure S1). Phage display libraries were generated by PCR-amplification of 
the VHH-repertoire from blood lymphocytes obtained 4–10 days after the last boost immunization18,20. CD38-
specific nanobodies were selected by binding of phages to CD38-transfected lymphoma cells. Selected clones 
were sequenced and clones that were found more than once, or a plurality of clones with one or a few amino acid 
substitutions in the CDR regions, were defined as a family. The results revealed selection of clones derived from 
22 distinct nanobody families, with CDR3 lengths ranging from 3 to 21 amino acid residues. FACS analyses per-
formed with crude periplasmic lysates from E. coli to detect nanobodies that bound to CD38-transfected but not 
to untransfected cells, confirmed the specificity of the selected nanobody families for CD38 (Figure S2a).
Table 1 provides an overview of the CD38-specific nanobodies. For each family, the number of isolates (rang-
ing from 1–27) and the number of variants within a family (ranging from 1–6) and the variant amino acid posi-
tions within the CDR3 region are indicated. Some nanobodies showed only little if any intrafamily variation, 
while others contained members with highly divergent amino acid sequences. Families 5, 14, and 20 contain the 
three nanobodies (MU375, MU1053, MU551) described in our previous study reporting the 3D-structures of 
these nanobodies in complex with CD3821.
Characterisation of monovalent CD38-specific nanobodies carrying a C-terminal His6-c-Myc tag. 
For each nanobody family, we subcloned the member that had shown the highest staining intensity of 
CD38-transfected cells in the periplasmic screening assay (Figure S2b). To circumvent the problem of endotoxin 
contamination of nanobodies inherent to the E. coli expression system, we recloned the nanobody encoding 
region into a eukaryotic expression vector (pCSE2.5) optimized for secretory protein production in suspension 
cultures of HEK-6E cells in serum free medium22–24. SDS-PAGE analyses of HEK cell culture supernatants har-
vested 6d after transfection revealed consistent production levels of ~50 µg nanobody per ml of HEK-6E super-
natant (Figure S3).
Specific binding of purified CD38 nanobodies were determined by off-rate analysis on real time bio-layer 
interferometry (BLI) analysis using the immobilized ectodomain of human CD38 (Table 1), revealing disso-
ciation rates ranging from 7.8 × 10−5 to 6.5 × 10−3 s−1. Several nanobodies had very slow off-rates below the 
detection limit of the instrument (WF121, WF139, MU1105 and WF124). As reference, the single chain variable 
fragment (scFv) of Daratumumab (see below) was included (kd of 4.4 × 10−3 s−1). In addition, qualitative com-
parisons of the dissociation rates were performed using fluorochrome-conjugated CD38 nanobodies bound to 
CD38-transfected cells by flow cytometry over a timeframe of 16 hours (Figure S4). The results confirm the strong 
binding and slow dissociation from native CD38 on the cell-surface by monovalent CD38-specific nanobodies.
Three nanobody families inhibit and two nanobody families stimulate the enzymatic activity 
of CD38. Nanobodies directed to enzymes reportedly show a propensity to block enzymatic activity25,26. CD38 
catalyzes the synthesis of cyclic ADP-ribose and ADP-ribose from NAD+ and the synthesis of cyclic GDP-ribose 
(cGDPR) from nicotinamide guanine dinucleotide (NGD+)4. Since the latter can be monitored conveniently by 
fluorimetry, we used this GDPR-cyclase assay to analyze the capacity of CD38-specific nanobodies to modulate 
the enzymatic activity of CD38. CD38-specific nanobodies from 22 families were analysed for their capacity to 
modulate the GDPR-cyclase activity of CD38 (Fig. 1). Three nanobodies (JK2, MU1067, MU523, families 4, 20, 
19) inhibited the conversion of NGD+ to cGDPR by recombinant CD38 in a dose-dependent manner. Two other 
nanobodies (WF14 and MU738, families 7 and 9) enhanced CD38-catalyzed synthesis of cGDPR.
Crossblockade analyses reveal binding of nanobodies to three non-overlapping epitopes. 
Next, we aimed to assess whether the selected nanobodies recognize overlapping or distinct epitopes on CD38. 
To this end, we performed crossblockade flow cytometry analyses with Alexa647-conjugated nanobodies from 
nine different families in the presence of excess unlabeled nanobodies (Table 2, Figure S5). The results allowed 
grouping of the selected nanobodies into three distinct non-overlapping bins. Group 1 nanobodies block binding 
of nanobodies MU1068 (family 12), WF211 (family 17), and MU274 (family 13). These nanobodies recognize 
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an overlapping epitope designated epitope 1. Similarly, group 2 nanobodies recognize an epitope overlapping 
with the binding epitope of nanobodies JK2 (family 4), MU1067 (family 20), and MU523 (family 19), designated 
epitope 2. Of note, these three epitope-2 nanobodies are the most potent antagonists of the enzyme activity of 
CD38 (Fig. 1). Group 3 nanobodies block binding of nanobodies JK19 (family 15), JK36 (family 2) and WF100 
(family 22) designated epitope 3.
Four nanobody families bind CD38 independently of daratumumab. In order to perform com-
parative binding analyses with monovalent CD38 nanobodies, we cloned the antigen-binding domain of daratu-
mumab in a monovalent scFv format, designated Dara scFv (Figure S6). We performed cross-blockade analyses 
with Alexa647 conjugated Dara scFv to determine which of the CD38-specific nanobodies could bind to CD38 
independently of Dara scFv. Interestingly, binding of Dara scFv was blocked by preincubation of CD38-expressing 
cells with nanobodies from each of the three epitope groups, including all epitope 1 families (Table 2, Figure S5). 
Three nanobodies did not interfere with binding of Dara scFv: one out of three epitope group 2 (JK2, family 4) 
and two out of eight epitope group 3: WF9 and JK36, (families 1 and 2). Two additional epitope group 3 nanobod-
ies, MU1105 and WF14 (families 7 and 22) partially blocked binding of Alexa647-Dara scFv.
In addition, the complete panel of nanobodies from 22 families and Dara scFv was assessed for in-tandem 
binding by BLI analysis to allow further mapping of subgroups within the three main clusters. Nanobodies were 
non-conjugated and simultaneous binding was assessed in both orders, i.e. injection as first or second analyte 
(Fig. 2, Table S1). Within epitope group 1, several families competed with a selection of families within epitope 
group 3, which may indicate that these families recognize a bridging epitope located between 1 and 3. For most 
nanobodies binding was independent of the order of injection, but for some, like WF14 in family 7 and MU738 
in family 9, the tandem binding profile was different dependent on the order. Interestingly, families 7 and 9 were 
identified as potentiators of CD38 enzyme activity (Fig. 1), and hence it is conceivable that these sensitize CD38 
by stabilization of a more active conformation.
These results of in-tandem epitope binning analyses of Dara scFv with CD38-specific nanobodies confirmed 
the independent binding of Dara scFv and nanobody families 1, 2, and 4. Moreover, three distinct members of 
family 22 were shown to bind CD38 in conjunction with Dara scFv, irrespective of the order of injection, while 
binding of family 7 was only observed when Dara scFv was allowed to bind first, in support of a conformational 
family llama isolate variant
max 
diff CDR3 name clone Kdis s−1 epitope
1 538 3 2 1 AHTFSGSF l-8.1b WF9 2.2E-03 3
2 539 6 6 10 DHTFAGVY l-8.2a JK36 2.0E-04 3
3 539 1 1 0 VIRTYSTY l-8.3a WF42 3.8E-04 3
4 538 4 4 8 WHYAAGRDY l-9.1c JK2 1.1E-03 2
5 25 4 2 11 ASTAVGADT l-9.2a MU370 5.1E-04 1
6 538 2 2 8 GNPGTRYIY l-9.3b JK29 1.8E-04 1
7 538 2 2 3 DRFSVVAVEYDY l-12b WF14 6.3E-03 3
8 539 3 3 2 GLKRIGDQREADY l-13a JK28 6.3E-04 1
9 10 13 5 14 DRFVVAAGTHDLDY s-14a MU738 2.9E-03 1
10 538 1 1 0 DRFTLVPTTSDLDY l-14.1a JK44 2.4E-04 1
11 539 4 4 7 RFWIGVRAPAEYNY l-14.2b JK22 3.2E-03 1
12 25 3 3 39 DRLVLVALSIADPGF l-15.1b MU1068 2.1E-04 1
13 25 27 2 21 GFPVLVALSIADPDY l-15.2a MU274 1.1E-04 1
14 10 9 1 0 GRGIVAGRIPAEYAD l-15.3a MU1053 9.0E-04 1
15 539 1 1 0 GRTASASTMIREYDS l-15.4a JK19 1.1E-04 3
16 10 9 2 2 TTSVVVLLAPNWYEY l+/−15a MU415 1.1E-03 1
17 538 1 1 0 RLRGWITTRKPNEYDY s-16a WF211 4.5E-03 1
18 25 4 3 13 ARSAGLGSSRRIEGYDK l-17a WF121 2.3E-04 3
19 25 9 2 20 QYQDRYYDEFTWKEKDMDY l-19.1a MU523 7.8E-05 2
20 25 3 2 6 RYQPRYYDSGDMDGYEYEF l-19.2a MU1067 1.2E-04 2
21 25 2 2 14 ADRFRGWATWRDDPDQYDY s-19b WF139 2.2E-04 3
22 10 6 6 13 DVTLNPFTGWDTRSGPMYRYEYDY s+/−24a WF100 5.1E-04 3
Daratumumab VL: RSN VH: DKILWFGEPVFDY c-13 Dara scFv 4.4E-03 1
Table 1. Characteristics of CD38-specific nanobody families. Families were designated in order of increasing 
CDR3 lengths. Isolate indicates the number of clones selected per family, variant indicates the number of 
clones carrying distinct but evidently related amino acid sequences, max diff indicates the maximum difference 
between two members of a family in number of amino acid substitutions. Variant amino acid positions in the 
CDR3 within a family are indicated in italic. Names indicate the presence of a short (s) or long hinge (l), the 
absence (−) or presence (+) of a disulfide bond connecting CDR2 and CDR3, and the length of the CDR3 
in numbers of amino acid residues. Kdis shows off-rates determined by SPR analyses on the immobilized 
glycosylated extracellular domain of CD38. Epitopes are numbered arbitrarily, with nanobodies that block the 
binding of one another considered to recognize the same or overlapping epitopes.
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mechanism (Figure S7, Table S1). Hence within epitope group 3, families 1, 2 and 22, and within epitope group 
2, family 4, represent subgroups that bind to an epitope that is non-overlapping with Dara scFv. Taken together, 
CD38 nanobodies from 4 distinct families and two non overlapping epitope groups are capable of binding CD38 
in conjunction with Dara scFv.
Nanobodies bind to human CD38 on lymphoma cell lines, peripheral blood NK and B cells, and 
primary myeloma cells. Next, purified fluorochrome-conjugated monovalent anti-CD38 nanobodies were 
analyzed for binding to native CD38 on the cell surface of human tumor cells, NK cells and B cells (Fig. 3). The 
results confirm high level of CD38 expression by established tumor cell lines derived from multiple myeloma 
(LP-1) and Burkitt’s lymphoma (CA46, Daudi) (Fig. 3a). On peripheral blood leukocytes of normal donors, all 
Figure 1. Identification of nanobodies that inhibit or enhance the enzymatic activity of CD38. (a) Recombinant 
human CD38 (5 nM) was incubated in the presence of CD38-specific nanobodies (400 nM) with NGD+ at 
RT. Production of cyclic GDP-ribose was monitored by fluorimetry (RFU = relative fluorescence units). Bars 
indicate the slope of the curves during the linear phase, e.g. from t = 10 min to t = 20 min) (n = 3). Bars are color 
coded according to the epitopes recognized by the respective nanobodies (grey = epitope 1, white = epitope 2, 
black = epitope 3, see Table 2). (b) Curves are shown for the enzymatic activity of CD38 (5 nM) in the presence 
of the two strongest agonistic nanobodies (WF14, MU738) and the two strongest antagonistic nanobodies (JK2, 
MU1067, and MU523), each at 0.4 nM, 40 nM, and 400 nM.
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nanobodies showed high level staining of CD16+ NK cells and a subset of CD19int B cells and much lower staining 
of T cells and CD19hi B cells, consistent with the known expression of CD38 by these cells (Fig. 3b). The same 
staining pattern was observed with the conventional mAb LS198–4–3 that is commonly used for routine diag-
nostics. We further analyzed the utility of the nanobodies to detect tumor cells in primary bone marrow samples 
from patients with multiple myeloma. The results show specific discrimination of myeloma cells (CD45lo/CD56hi) 
with CD38-specific nanobodies (Fig. 3c).
We next set out to determine whether the nanobodies that bind independently of Dara scFv to a 
non-overlapping epitope could also stain tumor cells in a therapeutic setting, i.e. when saturated with intact dara-
tumumab. To this end, we preincubated LP-1 myeloma cells with a large excess of Darzalex® before incubation 
with fluorochrome conjugated nanobodies (Fig. 4). The results show that nanobodies JK2 and JK36 effectively 
stain cell surface CD38 even after opsonization with daratumumab.
Specific detection of CD38+ tumors in vivo with nanobody MU1067 conjugated to the near 
infrared dye Alexa680. Next we determined whether CD38-specific nanobodies could be used as imaging 
agents to detect CD38 expressing tumors in vivo (Fig. 5). To this end we used a two-sided tumor model in nude 
mice bearing untransfected and CD38-transfected lymphoma cells injected subcutaneously in the left and right 
flanks. In order to allow in vivo imaging with the IVIS200 system, nanobody MU1067 was conjugated to the 
near infrared dye ALexa680 and specific binding of Alexa680-MU1067 to CD38-expressing cells was confirmed by 
flow cytometry. Seven days after injection of tumor cells, Alexa680-MU1067 (50 µg/mouse, 2.5 mg/kg) specifically 
detected CD38+ tumors in vivo already within 1 hour after nanobody injection (Fig. 5a,b). At this time point very 
strong signals were also detected in the kidneys, consistent with renal excretion of excess unbound nanobody 
(15 kD). At 2 hours after injection, signals from the CD38+ tumor exceeded those of the kidneys. At the time of 
sacrifice (48 h post injection) the CD38+ tumors continued to show high signals, while signals in other tissues 
returned to background levels (Fig. 5c), with low fluorescent signals still detectable in kidneys. While the liver 
itself showed only background fluorescence, fluorescent signals in the gall bladder at the time of sacrifice likely 
reflect biliary excretion of fluorochromes. In conclusion, in the time window from 2–24 h post injection, high 
tumor/background ratios were observed in all animals (Fig. 5b).
Figure 2. In-tandem binding analyses of nanobodies to immobilized recombinant CD38 by BLI. Sequential 
binding analyses of nanobodies to the glycosylated extracellular domain of CD38 immobilized on AR2 
Biosensors were performed using the Octet RED384. Hierarchial clustering was performed using the Ward’s 
method. Y-axis refers to first loaded analyte, Y-axis to second analyte. White: no additional binding of the 
second agent was observed, e.g. epitope was occupied or hindered by the loaded agent. Green: additional 
binding of the second agent was observed. Self-binning is indicated along the diagonal in white boxes.
www.nature.com/scientificreports/
6Scientific RepoRts | 7: 14289  | DOI:10.1038/s41598-017-14112-6
Figure 3. Fluorochrome-conjugated nanobodies detect CD38 on the surface of lymphoma cell lines, 
peripheral blood lymphocytes, and primary myeloma cells. (a) Untransfected mouse lymphoma cell lines Yac-1 
and DC27.10 and their counterparts stably transfected with human CD38 (top row of panels) and human 
lymphoma cell lines (bottom row) were stained with Alexa647-conjugated nanobody MU1067 or an irrelevant 
control nanobody. (b) Blood samples from normal donors were incubated with fluorochrome-conjugated 
antibodies against CD45 (pan-lymphocytes), CD56 (NK cells), CD19 (B cells) and CD3 (T cells) and CD38-
specific mAb LS1983-4-3, Nb JK36, or a control nanobody for 30 min at RT. Erythrocytes were lysed and cells 
were analyzed by flow cytometry. Gating was performed on CD45+ lymphocytes. (c) Bone marrow samples 
from two myeloma patients were incubated with fluorchrome-conjugated antibodies against CD45 and CD56 
and nanobody MU1067 for 30 min at RT. Erythrocytes were lysed and cells were analyzed by flow cytometry. 
Gating was performed on lymphocytes. Myeloma cells in these patients express CD56 but do not express CD45.
www.nature.com/scientificreports/
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Discussion
The goal of this study was to generate nanobodies directed against the cell surface ecto-enzyme CD38 as new 
diagnostic and potential therapeutic tools for hematological malignancies. We successfully identified 22 families 
of CD38-specific nanobodies from phage display libraries generated from immunized llamas. Our results show 
Figure 4. Fluorochrome-conjugated nanobodies JK2 and JK36 detect CD38 on the surface of human 
lymphoma cell lines saturated with daratumumab. LP-1 myeloma cells were preincubated with a saturating dose 
of DarzalexR, (daratumumab, human IgG1) (grey histograms) or with PBS (open histograms) before addition 
of fluorochrome-conjugated CD38-specific mAb LS198-4-3 or monovalent nanobodies WF211, JK2, or JK36. 
After incubation for 20 min at 4 °C cells were washed and analyzed by flow cytometry. Dashed lines = unstained 
cells.
Figure 5. Alexa680-conjugated nanobodies provide excellent discrimination of CD38+ tumors in vivo. 
Untransfected DC27.10 mouse lymphoma cells and DC27.10 cells stably transfected with human CD38 were 
injected subcutaneously in the left and right flanks of Nude mice. Seven days after tumor implantation, 50 µg 
of Alexa-680-conjugated nanobody MU1067 was injected into the tail vein. (a) Optical molecular imaging 
was performed before and at the indicated time points after nanobody injection. Signals below the tumors 
correspond to the kidneys. Signals on the tail and feet likely reflect contact with urine containing labeled 
nanobodies. (b) T/B ratios were determined from regions of interests (ROIs) drawn around tumors and 
normal tissue (hind leg) for semi-quantitative analyses. T/B ratios were calculated by subtracting background 
signals from radiant efficiencies of ROIs around tumors. T/B ratios are plotted as a function of time. (c) Optical 
molecular imaging of tissues removed after sacrifice 48 h after nanobody injections.
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that some of these nanobodies modulate the enzymatic activity of CD38 and allow specific detection of CD38 
expressing tumors in vivo.
11 of 22 nanobody families were obtained from protein-immunized llamas after panning on the aglycosylated 
CD38 ectodomain, the other 11 nanobody families were obtained from cDNA-immunized llamas by binding 
to CD38-transfected cells in solution. Since the four llamas used were outbred and genetically diverse, it is not 
possible to conclude that one or the other strategy is better. However, it is perhaps noteworthy that three of four 
families that bind CD38 independently of daratumumab (families 1, 2, and 4) were derived from genetic immu-
nizations whereas the clone with the highest affinity (MU523, family 19) was derived from a llama immunized 
with protein.
All CD38 nanobodies bind to three independent non-overlapping epitopes (Fig. 6a). Interestingly, all nano-
bodies from epitope binning group 1 and many nanobodies from epitope groups 2 and 3 interfered with binding 
of Dara scFv. The nanobody CDR3 loop can fold over a side of the variable domain to increase the interaction 
surface with the antigen and the solvent accessible surface area of a nanobody can be as large as that of a VH-VL 
pair25. However, the size of the pair of variable domains of Dara scFv is roughly twice as large as that of a the 
single variable domain of a nanobody. Consistently, the results of the tandem epitope binning analyses by Octet 
show that the binding site of Dara scFv is larger than that of the CD38-specific nanobodies. Although there is no 
structural data available on the binding of Daratumumab, it presumably uses both its VH and VL domains for 
binding to CD38, i.e. it can be expected to cover roughly twice as large a surface area of CD38 than the nanobod-
ies. One nanobody family of epitope group 1 (JK2, family 4) and a subgroup of three nanobody families within 
epitope group 3 (WF9, JK36, and MU1105, families 1, 2 and 22) bound CD38 independently of daratumumab. 
Nanobodies JK2 and JK36 effectively recognize cell surface CD38 even after opsonization with saturating doses 
of daratumumab. These nanobodies could potentially be used to monitor expression of CD38 on the cell surface 
of lymphocytes and tumor cells in daratumumab-treated patients.
We have previously determined the precise epitopes of three different CD38 nanobodies within epitope 
groups 1 and 2 by co-crystallisation with the CD38 ectodomain (Fig. 6b). Structural information for nanobodies 
MU375 (fam 5, epitope 1), MU1053 (fam 14, epitope 1), and MU551 (fam 20, epitope 2) is available in PDB codes 
5F21, 5F1O and 5F1K, respectively21. All three nanobodies compete with the single chain variable fragment of 
daratumumab for binding to cells and to recombinant protein, suggesting overlapping epitopes. In line with this, 
Ser274 of CD38 (Fig. 6b), which is described to be important for daratumumab binding13, is part of the footprint 
on CD38 in each of the two epitope 1 nanobodies21. Within epitope group 1, family 14 differs from family 5 in that 
it competes with a subset of epitope group 3 nanobodies. The structural data confirms that MU1053 (fam14) is 
more directed to the hind site of the protein, further away from the catalytic pocket than MU375 (fam5).
Previous studies have uncovered a striking propensity of nanobodies from immunized llamas to bind to the 
active site of enzyme antigens20,23,25–27. In our study, three of 22 nanobody families, i.e. all epitope 2 nanobodies, 
blocked CD38-catalyzed conversion of NGD+ to cyclic GDPR in a dose dependent fashion, whereas two nano-
body families (families 7 and 9 from epitope groups 3 and 1, respectively) potentiated CD38 enzyme activity. In 
this context it is also of interest to note that only one of well over 100 monoclonal antibodies generated against 
CD38 has been shown to inhibit the enzyme activity of CD3828. The crystal structure of this mAb sar650984 
in complex with CD38 (Fig. 6b) revealed binding of sar650984 far away from the active site crevice (Fig. 6b), 
implying an allosteric mode of action28. It seems likely that the enzyme-inhibiting nanobodies similarly act in an 
allosteric fashion, considering that the binding site of the MU551 family 20 nanobody is also located away from 
the active site crevice (Fig. 6b). Similarly, the nanobodies that were found to sensitize the catalytic activity of 
CD38 may act in an allosteric manner, given the observation of conformational constraints for these nanobodies 
in the tandem binding studies. It has been suggested that metabolites of NAD+ generated by CD38 in the tumor 
microenvironment can promote tumor growth and immunosuppression8. Thus, it is conceivable that blocking the 
Figure 6. Venn diagram of binding epitopes and structure models of CD38 in complex with nanobodies and 
mAbs. (a) Venn diagram of binding epitopes on CD38 for nanobodies and the single chain variable fragment 
of daratumumab. Numbers indicate family numbers of CD38-specific nanobodies. (b) 3D-structures of CD38 
(yellow) in complex with NAD+ (orange), nanobodies MU375 (cyan, family 5), MU551 (grey, family 20), or the 
Fab fragment of mAb hb7 (red) or of mAb sar650984 (blue) were aligned with PyMOL using PDB-IDs 2i65, 
5f21, 5f10, 3raj, and 4cmh, respectively. Mutation of serine 274 (green) to phenylalanine abolishes binding of 
daratumumab.
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enzymatic activity of CD38 may be of therapeutic benefit in cancer. If so, this could influence the choice of nano-
bodies as therapy candidates for pre investigational new drug experiments. In particular, use of the antagonistic 
nanobody family 4 that binds independently of daratumumab, would be feasible even in patients undergoing 
daratumumab treatment. It will thus be interesting to determine whether allosteric modulation of CD38-enzyme 
activity in vivo by CD38 nanobodies can counteract its purported immunosuppressive and tumor promoting 
effects in the tumor microenvironment8.
In a subcutaneous xenograft tumor model in nude mice, we examined the capacity of CD38-specific nano-
bodies to specifically target CD38-expressing tumor cells. In this model, the subcutaneous location and the nude 
skin minimized quenching of fluorescent signals from the NIRF-conjuagted nannobodies by muscle, bone or hair 
and thus facilitated in vivo imaging. Moreover, since the nanobodies do not cross react with mouse CD38, the 
mouse model provided a clear background. The results of these experiments clearly demonstrate the capacity of 
nanobodies to specifically target CD38+ vs. CD38− tumors. In a clinical setting, radionuclide-labeled nanobodies 
can be expected to provide higher sensitivity at lower doses29, but higher background signals due to binding of 
nanobodies to endogenously expressed CD38 in healthy tissues. Besides the high specificity and affinity to CD38, 
the efficient imaging of CD38+ tumors can be attributed to the small size of the nanobody which allows excellent 
tissue and tumor penetration15,16,29 and fast clearance of excess unbound nanobodies from the circulation by renal 
excretion30. Hence the current panel of high affine monovalent CD38-specific nanobodies are attractive for use as 
companion diagnostic for anti-CD38 therapies.
For therapeutic applications, nanobodies can readily be humanized, e.g. by fusion to the hinge and Fc-domains 
of human IgG131. Moreover, the VHH domain itself can be humanized by substituting framework residues to 
more closely resemble those of human VH domains32. This is done routinely for llama-derived nanobodies in 
clinical development33,34.
Table 2. Epitope mapping of CD38-specific nanobodies.CA46 lymphoma cells were preincubated for 30 min at 
4 °C with unconjugated nanobodies (indicated on the left) before addition of Alexa647-conjugated nanobodies 
(indicated on top). Cells were further incubated for 30 min at 4 °C, washed and analyzed by flow cytometry. 
Numbers indicate the percentage maximal blockade of the mean fluorescence intensity of cells labeled in the 
absence of competing nanobodies, negative numbers indicate enhanced labeling of cells in the presence of the 
competing nanobody. Inhibition of binding by 50–80% is highlighted in light grey, inhibition of binding by 
>80% in dark grey. Self-blockade by the nanobody used for labeling is indicated by highlighted boxes in the 
diagonal.
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In conclusion, our results underscore the potential of nanobodies for modulating the enzymatic activity of 
CD38 and for specific in vivo detection of CD38+ tumors. Importantly, we describe four nanobody families 
that bind independently of daratumumab, which could potentially be valuable for monitoring the efficacy of 
daratumumab therapy since they can still detect CD38 after binding of daratumumab. The nanobodies reported 
here thus hold promise as new diagnostic and potential therapeutic tools for multiple myeloma and other 
CD38-expressing malignancies.
Methods
Protein production and llama immunizations. The extracellular domain (aa 46–300) of a variant of 
CD38 in which the three potential N-linked glycosylation sites were inactivated was produced as a secretory pro-
tein in yeast cells and purified as described previously3. The extracellular domain of CD38 (aa46–300) with intact 
glycosylation sites was produced as a secretory protein with a chimeric His6x-Myc epitope tag in the pCSE2.5 
vector22 (kindly provided by Dr. Thomas Schirrmann, Braunschweig). For cDNA immunization the full-length 
open reading frame of CD38 was cloned into the pEF-DEST51 expression vector. Two llamas (Lama glama) 
(designated 10, 25) were immunized subcutaneously with purified recombinant aglycosylated protein emulsified 
with Specol adjuvant (240 µg in 500 µl total volume)20,27,35. Two llamas (designated 538 and 539) were immunized 
by ballistic cDNA immunization20,36. The humoral immune response was monitored in serially diluted serum 
by ELISA on microtiter plates (Nunc MaxiSorp, Thermo Fisher Scientific, Waltham, MA) coated with recom-
binant CD38, using monoclonal antibodies directed against llama IgG2 and IgG3 kindly provided by Dr. Judith 
Appelton, Cornell University, NY37. Animals were bled 4–18 days after the 3rd or 4th boost.
Cells. The Yac-1 and DC27.10 mouse lymphoma cell lines were transfected with linearized full-length human 
CD38 expression vector pEF-DEST51. Stable transfectants were selected in medium containing blasticidin 
and by fluorescence activated cell sorting. Human multiple myeloma (RPMI-8266, U266, LP-1) and Burkitt’s 
lymphoma (CA46, DAUDI) cell lines were obtained from the Leibniz-Institute DSMZ-German Collection of 
Microorganisms and Cell Cultures, Braunschweig, Germany. Bone marrow aspirates of patients MM123 and 
MM129 were obtained after written informed consent as approved by the ethics committee (Ethikkommission 
der Ärztekammer Hamburg, PV4767).
Construction of phage display library and selection of CD38-specific nanobodies. Mononuclear 
cells were isolated from 120 ml of blood by Ficoll-PaqueTM (GE Healthcare, Chalfont St Giles, UK) gradient 
centrifugation. RNA purified from these cells by TRIZOL reagent (Invitrogen, Carlsbad, CA) was subjected to 
cDNA synthesis with random hexamer primers. The VHH coding region was amplified by PCR with degenerate 
VHH-specific primers20,23. PCR products were purified from agarose gels, digested sequentially with SfiI and NotI 
(NEB, Ipswich, MA) and cloned into the pHEN2 phagemid vector downstream of the PelB-leader peptide and 
upstream of the chimeric His6x-Myc epitope tag27,38. Transformation into XL1-Blue E. coli (Stratagene, La Jolla, 
CA) yielded libraries with sizes of 4.0 × 105–107 clones. Phage particles were precipitated with polyethylene glycol 
from culture supernatants of E. coli transformants infected with a 10-fold excess of M13K07 helper phage (GE 
Healthcare, Chalfont St Giles, UK).
Panning of specific phage was performed using either the recombinant aglycosylated human CD38 ectodo-
main immobilized on microtiter plates (Nunc MaxiSorp, Thermo Fisher Scientific, Waltham, MA) or in solu-
tion with CD38-transfected Yac-1 cells. Phage particles (1.6 × 1011) were incubated with recombinant CD38 
or CD38-transfected cells for 60 min with agitation at room temperature in PBS, 10% Carnation non-fat dry 
milk powder (Nestlé, Glendale, CA). Following extensive washing, bound phages were eluted from ELISA plates 
with 50 mM diethylamine and neutralized with 1 M Tris-HCl pH 8. Phages were eluted from transfected cells by 
trypsinization. Eluted phages were titrated and subjected to one or two more rounds of panning, following the 
same procedure. Phage titers were determined at all steps by infection of TG1 E. coli cells (Stratagene, La Jolla, 
CA). Plasmid DNA was isolated from single colonies and subjected to sequence analyses using pHEN2-specific 
forward and reverse primers.
Production and reformatting of nanobodies. Monomeric nanobodies were expressed in HB2151 E. coli 
cells (GE Healthcare, Chalfont St Giles, UK)20,23. Protein expression was induced with IPTG (Roche, Rotkreuz, 
Switzerland) when bacterial cultures had reached an OD600 of 0.5 and cells were harvested after further cultivation 
for 3–4 h at 37 °C. Periplasmic lysates were generated by osmotic shock and removal of bacterial debris by high 
speed centrifugation. Nanobodies were readily purified from E. coli periplasmic lysates by immobilized metal 
affinity chromatography (IMAC).
The coding region of selected nanobodies was subcloned using NcoI/PciI and NotI upstream of a chimeric 
His6x-Myc epitope tag into the pCSE2.5 vector22 (kindly provided by Thomas Schirrmann, Braunschweig). 
Daratumumab scFv was generated by gene synthesis using the published sequence (WO 2011/154453) by fusing 
the VH domain and the VL domain via a 15GS linker flanked by NcoI and NotI sites and cloned upstream of a 
chimeric His6x-Myc epitope tag into the pCSE2.5 vector.
Recombinant myc-his tagged nanobodies and Dara scFv were expressed in transiently transfected HEK-6E 
cells cultivated in serum-free medium23,36. Six days post transfection, supernatants were harvested and cleared 
by centrifugation. Nanobodies in cell supernatants were quantified by SDS-PAGE and Coomassie staining rela-
tive to marker proteins of known quantities: 10 µl samples of the supernatant were size fractionated side by side 
with standard proteins (albumin 4 µg, IgH 2 µg, IgL 1 µg, lysozyme 0.4 µg; albumin 1 µg, IgH 0.5 µg, IgL 0.25 µg, 
lysozyme 0.1 µg). Yields of recombinant nanobodies typically ranged from 0.5–3 µg/10 µl. Myc-His tagged nano-
bodies were purified by immobilized metal affinity chromatography using Ni-NTA agarose (Sigma, St Louis, 
MO).
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ELISA. Recombinant CD38 (100 ng/100 µl PBS/well) was adsorbed to 96-well Nunc MaxiSorp plates (Thermo 
Fisher Scientific, Waltham, MA) at 4 °C over night. Wells were washed twice with PBS and blocked for 2 hours 
with PBS containing 5% nonfat powdered milk at room temperature. Wells were incubated for 30 min with llama 
pre and immune serum (diluted 1:100 in PBS). Following washing with PBS/0.05% Tween 20, bound antibodies 
were detected with llama IgG-specific mAbs followed by peroxidase-conjugated anti-mouse IgG (Jackson) and 
(TMB) (Sigma, St Louis, MO) as substrate. The absorbance at 450 nm was measured using a Victor3 ELISA-reader 
(Perkin-Elmer, Waltham, MA).
Off-rate determination. Off-rates of CD38 nanobodies were determined by BLI technology, using an 
Octet RED384 instrument (ForteBio). As running buffer HBS-EP + (0.01 M HEPES pH 7.4, 0.15 M NaCl, 3 mM 
EDTA, 0.05% v/v Surfactant P20) was used. Assays were performed at 25 °C. The shake speed during the bio-
sensor preparation and off-rate determination was set at 1000 rpm. Amine reactive 2nd Generation (AR2G) 
biosensors (ForteBio) were activated for 10 minutes with EDC(20 mM)/NHS(10 mM) and recombinant human 
CD38 was loaded at 10 µg/ml in 10 mM sodium acetate pH 6 for 15 min. After immobilization, surfaces were 
deactivated with 1 M ethanolamine (pH 8.5) for 10 min. During off-rate screening 100 nM and 1 µM nanobody 
were allowed to associate during 5 min on immobilized human CD38 followed by a 10 min dissociation. After 
each cycle the human CD38 surfaces were regenerated via 5 short pulses of 5 s of 100 mM HCl and running 
buffer. Data processing and off-rate determination was performed with ForteBio Data Analysis Software Version 
9.0.0.12. Sensorgrams were double referenced by subtracting 1) running buffer on reference biosensor containing 
only human CD38 and 2) nanobody interaction on parallel reference biosensors on which no human CD38 was 
immobilized. Processed curves were evaluated via a fitting with the model ‘1:1’.
CD38 epitope binning. In-tandem epitope binning of CD38-specific nanobodies and Dara scFv was 
performed on an Octet RED384 instrument (ForteBio). As running buffer HBS-EP + (0.01 M HEPES pH 7.4, 
0.15 M NaCl, 3 mM EDTA, 0.05% v/v Surfactant P20) was used. Experiments were performed at 20 °C. The shake 
speed during the biosensor preparation and epitope binning was set at 1000 rpm. Amine reactive 2nd Generation 
(AR2G) biosensors (ForteBio) were activated for 10 min with EDC(20 mM)/NHS(10 mM) and human CD38 
protein was loaded at 10 µg/ml in 10 mM sodium acetate pH6 for 15 min. After immobilization, surfaces were 
deactivated with 1 M ethanolamine (pH 8.5) for 10 min. In the epitope binning, 100 nM nanobody 1 was loaded 
during 3 min on immobilized CD38 to saturate all available epitopes. Nanobody 2 was presented after a 10 s dip in 
running buffer for 3 min followed by a 1 min dissociation. After each cycle the human CD38 surfaces were regen-
erated via 5 short pulses of 5 s each of 100 mM HCl followed by running buffer. Data was processed with ForteBio 
Data Analysis Software Version 9.0.0.12. Binding levels of nanobody 2 were determined at the end of the 3 min 
association and compared to levels at baseline (beginning of association). Irrelevant nanobody controls were 
included. The binding level of nanobody 2 for each nanobody 2 - nanobody 1 pair was divided by the binding 
response of nanobody 2 on a CD38 surface saturated with nanobody 2 (self-binning). Normalized data was hier-
archically clustered using Ward’s method (distance measure: half square Euclidian distance; scale: logarithmic) 
and visualized in Spotfire (TIBCO Software Inc.).
Fluorimetric enzyme assay. CD38 catalyzes both, the synthesis of cADPR and nicotinamide from 
β-NAD+, and the fast hydrolysis of cADPR to ADPR. A fluorimetric enzyme assay with slower kinetics has 
been developed using nicotinamide guanine dinucleotide (NGD+) as substrate4. NGD+ is converted to cyclic 
GDP-ribose (cGDPR) and nicotinamide followed by a very slow hydrolysis of cGDPR to GDPR, leading to accu-
mulation of the fluorescent product cGDPR. Enzymatic production of cGDPR from NGD+ (80 µM, Sigma, St 
Louis, MO) was monitored continuously for 50 min at 410 nm (emission wavelength) with an excitation wave-
length set at 300 nm, using a Hitachi F-2000 fluorimeter. Anti-CD38 nanobodies were pre-incubated at a final 
concentration of 400, 40, 4, and 0.4 nM with 5 nM recombinant glycosylated extracelluar domain of CD38 for 
15 min at RT before addition of NGD+ and further incubation in the dark at RT in triplicate wells for each treat-
ment. Readings (EX300/EM410) from wells without CD38 were subtracted from all sample readings and were 
plotted for each nanobody concentration in Relative Fluorescence Units (RFU) vs. time. The rate of cGDPR pro-
duction was calculated as the slope of these curves (RFU/s) during the linear phase of the reaction, i.e. between 
t = 10 min and t = 20 min.
Flow cytometry. Untransfected Yac-1 cells and Yac-1 cells stably transfected with human CD38 were 
incubated for 30 min with nanobody-containing periplasmic lysates (diluted 1:10 in PBS). Following washing 
with PBS/0.1% BSA, bound nanobodies were detected with FITC-conjugated anti-c-Myc mAb 9E10 (Sigma, 
St Louis, MO). Human tumor cell lines, peripheral blood leukocytes, and bone marrow cells were incubated 
for 30 min with fluorochrome-conjugated nanobodies and monoclonal antibodies directed against CD3 
(SK7), CD16 (3G8), CD19 (HIB19), CD45 (HI30), and CD38 (LS198–4–3) (BD Biosicences, Heidelberg and 
Beckman-Coulter, Krefeld). Darzalex® was purchased from Janssen-Biologics, Leiden. For binding stability 
analyses, CD38-transfected cells were incubated for 60 min with serial dilutions of monovalent nanobodies 
in PBS/0.1% BSA. Cells were washed three times with PBS/0.1% BSA. Bound antibodies were detected with 
FITC-conjugated anti-c-Myc mAb 9E10 (BioLegend).
For nanobody dissociation analyses, two separate aliquots of CD38-transfected cells were incubated either 
with Cell Proliferation Dye eFluor 450 (eBioscience) or with Alexa647-conjugated nanobodies for 20 min at 4 °C. 
Cells were washed four times, mixed at a 1:1 ratio and further incubated at 4 °C or at 37 °C for 0.5, 2, or 16 h before 
FACS analyses. The dissociation of nanobodies from the target cells and association with the eFluor 450 labeled 
cells was analyzed using the FlowJo software (Treestar).
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Cross-blockade analyses. For epitope analyses, cells were preincubated with excess monovalent nano-
bodies or Dara scFv (2 µg/100 µl PBS/0.1% BSA) for 30 min at RT before addition of fluorochrome-conjugated 
nanobodies (500 ng in 0.5 µl PBS) and further incubation for 20 min at RT. Cells were washed and analyzed by 
flow cytometry on a BD-FACS Canto. Data were analyzed using the FlowJo software (Treestar).
In vivo and ex vivo imaging. Tumor graft experiments were conducted using athymic nude mice 
(NMRI-Foxn1nu) obtained from Charles River Laboratories (Sulzfeld, Germany). Experiments were performed 
in accordance with international guidelines on the ethical use of animals and were approved by the animal wel-
fare commission (Amt für Verbraucherschutz, Lebensmittelsicherheit und Veterinärwesen Hamburg, Nr. 17/13). 
Prior to optical molecular imaging in vivo, 8–10-week-old mice were kept on an alfalfa-free diet for 7 d to min-
imize autofluorescence of the intestine. For generation of tumor grafts, mice were injected s.c. on the right side 
with 1 × 106 CD38-transfected DC.27.10 cells and on the left side with 1 × 106 untransfected DC27.10 cells, each 
in 0.2 ml of a 50:50 mix of RPMI medium and Matrigel (BD Biosciences, Franklin Lakes, USA). After 7 d, i.e. 
when tumors reached ~8 mm in diameter, 50 µg of Alexa647-conjugated nanobody MU1067 was injected i.v. via 
the tail vein. Similar doses have been found to yield good tumor to background ratios in previous studies using 
nanobodies conjugated to near infrared fluorochromes30,39. Optical molecular imaging was performed before 
injection and at indicated time points after injection. For optical molecular imaging, mice were anesthetized 
with isofluorane and positioned in the imaging chamber of a small animal imaging system (IVIS-200, Caliper 
Life Sciences, Hopkinton, Massachusetts, USA). After qualitative imaging in vivo, quantitative analyses were 
performed by placing ROIs around the CD38-positive tumors, the CD38-negative tumors (negative control) 
and the hind limb (background signal). Total radiant efficiency was determined with Living Image 4.2 software 
(Caliper Life Sciences). The tumor-to-background ratio was calculated by dividing the tumor uptake value by the 
background value. For ex vivo validation of in vivo measurements, animals were sacrificed 48 h post-injection. 
Tumors and organs (spleen, lungs, liver, kidneys, stomach, ileum, and muscle) were dissected and imaged with 
the IVIS-200.
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